Resverlogix Corp. (RVX.TO)
CAD 0.06
(0.0%)
CAD 0.06
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 8.11 Million USD | -18.7% |
| 2021 | 9.98 Million USD | 93137.44% |
| 2020 | 10.7 Thousand USD | -99.91% |
| 2019 | 11.37 Million USD | -30.14% |
| 2018 | 16.28 Million USD | 96.75% |
| 2017 | 8.27 Million USD | -23.82% |
| 2016 | 10.86 Million USD | -72.9% |
| 2015 | 40.09 Million USD | 89.53% |
| 2014 | 21.15 Million USD | 599.14% |
| 2013 | 3.02 Million USD | -85.24% |
| 2012 | 20.49 Million USD | 65.68% |
| 2011 | 12.37 Million USD | 46.81% |
| 2010 | 8.42 Million USD | -0.08% |
| 2009 | 8.43 Million USD | -55.39% |
| 2008 | 18.9 Million USD | -8.71% |
| 2007 | 20.7 Million USD | 38.09% |
| 2006 | 14.99 Million USD | 86.05% |
| 2005 | 8.06 Million USD | -20.96% |
| 2004 | 10.19 Million USD | 278.45% |
| 2003 | 2.69 Million USD | 149.02% |
| 2002 | 1.08 Million USD | 266.44% |
| 2001 | 295.29 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 7933.00 USD | -99.9% |
| 2023 Q2 | 7.88 Million USD | 99320.14% |
| 2023 Q3 | 7.82 Million USD | -0.77% |
| 2022 FY | 8.11 Million USD | -18.7% |
| 2022 Q4 | 8.11 Million USD | -21.07% |
| 2022 Q1 | 10.29 Million USD | 3.18% |
| 2022 Q2 | 10.03 Million USD | -2.61% |
| 2022 Q3 | 10.28 Million USD | 2.5% |
| 2021 FY | 9.98 Million USD | 93137.44% |
| 2021 Q4 | 9.98 Million USD | -11.59% |
| 2021 Q1 | 10.62 Million USD | 0.0% |
| 2021 Q2 | 14.1 Million USD | 32.8% |
| 2021 Q3 | 11.29 Million USD | -19.95% |
| 2020 Q1 | 11.37 Million USD | -6.19% |
| 2020 FY | 10.7 Thousand USD | -99.91% |
| 2020 Q2 | 10.52 Million USD | -7.52% |
| 2020 Q3 | 10.52 Million USD | 0.02% |
| 2019 Q4 | 12.12 Million USD | -9.29% |
| 2019 Q3 | 13.37 Million USD | -32.71% |
| 2019 Q2 | 19.87 Million USD | 22.01% |
| 2019 FY | 11.37 Million USD | -30.14% |
| 2019 Q1 | 16.28 Million USD | 13.08% |
| 2018 Q4 | 14.4 Million USD | 14.21% |
| 2018 FY | 16.28 Million USD | 96.75% |
| 2018 Q3 | 12.61 Million USD | -12.09% |
| 2018 Q2 | 14.34 Million USD | 73.29% |
| 2018 Q1 | 8.27 Million USD | -3.33% |
| 2017 Q3 | 9.77 Million USD | 2.15% |
| 2017 Q2 | 9.56 Million USD | -11.99% |
| 2017 Q1 | 10.86 Million USD | -19.57% |
| 2017 FY | 8.27 Million USD | -23.82% |
| 2017 Q4 | 8.56 Million USD | -12.35% |
| 2016 Q2 | 32.05 Million USD | -20.06% |
| 2016 FY | 10.86 Million USD | -72.9% |
| 2016 Q4 | 13.51 Million USD | -36.46% |
| 2016 Q1 | 40.09 Million USD | -3.34% |
| 2016 Q3 | 21.26 Million USD | -33.66% |
| 2015 Q1 | 21.15 Million USD | -0.5% |
| 2015 Q4 | 41.48 Million USD | -16.93% |
| 2015 FY | 40.09 Million USD | 89.53% |
| 2015 Q3 | 49.93 Million USD | -9.17% |
| 2015 Q2 | 54.98 Million USD | 159.88% |
| 2014 Q4 | 21.26 Million USD | -20.2% |
| 2014 Q3 | 26.64 Million USD | 627.27% |
| 2014 Q2 | 3.66 Million USD | 21.08% |
| 2014 Q1 | 3.02 Million USD | -3.54% |
| 2014 FY | 21.15 Million USD | 599.14% |
| 2013 Q2 | 5.56 Million USD | -72.84% |
| 2013 FY | 3.02 Million USD | -85.24% |
| 2013 Q4 | 3.13 Million USD | -22.22% |
| 2013 Q3 | 4.03 Million USD | -27.54% |
| 2013 Q1 | 20.49 Million USD | 46.26% |
| 2012 Q3 | 20.74 Million USD | 244.02% |
| 2012 Q1 | 12.37 Million USD | -30.81% |
| 2012 Q2 | 6.03 Million USD | -51.25% |
| 2012 FY | 20.49 Million USD | 65.68% |
| 2012 Q4 | 14.01 Million USD | -32.46% |
| 2011 FY | 12.37 Million USD | 46.81% |
| 2011 Q4 | 17.88 Million USD | 106.03% |
| 2011 Q1 | 8.42 Million USD | -23.8% |
| 2011 Q2 | 13.98 Million USD | 65.96% |
| 2011 Q3 | 8.67 Million USD | -37.94% |
| 2010 Q3 | 14.98 Million USD | -18.93% |
| 2010 FY | 8.42 Million USD | -0.08% |
| 2010 Q1 | 8.43 Million USD | -17.18% |
| 2010 Q4 | 11.05 Million USD | -26.18% |
| 2010 Q2 | 18.47 Million USD | 119.12% |
| 2009 Q4 | 10.18 Million USD | -11.16% |
| 2009 Q2 | 15.53 Million USD | -17.85% |
| 2009 FY | 8.43 Million USD | -55.39% |
| 2009 Q1 | 18.9 Million USD | 372.3% |
| 2009 Q3 | 11.46 Million USD | -26.2% |
| 2008 FY | 18.9 Million USD | -8.71% |
| 2008 Q1 | 20.7 Million USD | -20.18% |
| 2008 Q2 | 16.21 Million USD | -21.69% |
| 2008 Q3 | 7.26 Million USD | -55.19% |
| 2008 Q4 | 4 Million USD | -44.92% |
| 2007 Q3 | 29.44 Million USD | -10.18% |
| 2007 Q4 | 25.94 Million USD | -11.89% |
| 2007 Q2 | 32.78 Million USD | 118.6% |
| 2007 Q1 | 14.99 Million USD | -28.51% |
| 2007 FY | 20.7 Million USD | 38.09% |
| 2006 Q1 | 8.06 Million USD | -4.67% |
| 2006 FY | 14.99 Million USD | 86.05% |
| 2006 Q4 | 20.97 Million USD | 411.53% |
| 2006 Q2 | 6.36 Million USD | -20.98% |
| 2006 Q3 | 4.1 Million USD | -35.62% |
| 2005 Q4 | 8.45 Million USD | -10.51% |
| 2005 FY | 8.06 Million USD | -20.96% |
| 2005 Q1 | 10.19 Million USD | -1.22% |
| 2005 Q2 | 9.51 Million USD | -6.69% |
| 2005 Q3 | 9.44 Million USD | -0.71% |
| 2004 Q3 | 2.87 Million USD | 16.22% |
| 2004 Q4 | 10.32 Million USD | 259.35% |
| 2004 Q2 | 2.47 Million USD | -8.27% |
| 2004 Q1 | 2.69 Million USD | 37.8% |
| 2004 FY | 10.19 Million USD | 278.45% |
| 2003 Q2 | 865.8 Thousand USD | -19.99% |
| 2003 Q1 | 1.08 Million USD | -5.33% |
| 2003 Q3 | 823.97 Thousand USD | -4.83% |
| 2003 Q4 | 1.95 Million USD | 137.32% |
| 2003 FY | 2.69 Million USD | 149.02% |
| 2002 Q2 | 253.22 Thousand USD | -7.4% |
| 2002 Q3 | 238.62 Thousand USD | -5.77% |
| 2002 FY | 1.08 Million USD | 266.44% |
| 2002 Q4 | 1.14 Million USD | 378.97% |
| 2002 Q1 | 273.45 Thousand USD | 0.0% |
| 2001 FY | 295.29 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | -444.484% |
| Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | 69.633% |
| Helix BioPharma Corp. | 1.48 Million CAD | -444.997% |
| Microbix Biosystems Inc. | 35.65 Million CAD | 77.239% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | 57.589% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 81.681% |
| Oncolytics Biotech Inc. | 38.82 Million CAD | 79.096% |
| Sernova Corp. | 22.1 Million CAD | 63.292% |